Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 3 art units • 4 examiners • 2 of 4 (50%) have an AI response strategy ready • 2 patents granted in the last 365 days
Curie Co. Inc. has 4 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 4 distinct examiners and 3 distinct art units, showing examiner-level dispersion with some concentration at the art-unit level.
NEAGU, IRINA is the busiest examiner, with 1 pending matter. Because the examiner assignments are distributed, counsel should use centralized portfolio tracking while developing response strategies for each individual examination record.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (50%) |
| §112 only | 1 (25%) |
| Multi-statute (no §101) | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NEAGU, IRINA | 1 | 46.7% | +57.2% |
| EIX, EMILY FAY | 1 | 45.7% | +76.0% |
| MOAZZAMI, NAGHMEH NINA | 1 | 71.8% | +49.1% |
| ROBINSON, HOPE A | 1 | 67.7% | +43.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18737768 | ANTIMICROBIAL COMPOSITIONS | NEAGU, IRINA | 31d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18737768 | ANTIMICROBIAL COMPOSITIONS | NEAGU, IRINA | 31d overdue |
| 17910952 | TRANSGLUTAMINASE VARIANTS | ROBINSON, HOPE A | 20d |
| 18044226 | COMPOSITIONS AND METHODS OF USE THEREOF | EIX, EMILY FAY | — |
| 17998576 | TRANSGLUTAMINASE VARIANTS AND APPLICATIONS OF USE THEREOF | MOAZZAMI, NAGHMEH NINA | — |
| Art Unit | Apps |
|---|---|
| 1652 | 2 |
| 1629 | 1 |
| 1653 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18737768 | ANTIMICROBIAL COMPOSITIONS | NEAGU, IRINA | 1629 | §102§103§112 | Final Rejection | 31d overdue | AI Ready | Jun 07, 2024 |
| 18044226 | COMPOSITIONS AND METHODS OF USE THEREOF | EIX, EMILY FAY | 1653 | §103Other | Non-Final OA | — | Pending | Mar 07, 2023 |
| 17998576 | TRANSGLUTAMINASE VARIANTS AND APPLICATIONS OF USE THEREOF | MOAZZAMI, NAGHMEH NINA | 1652 | §103 | Non-Final OA | — | Pending | Nov 11, 2022 |
| 17910952 | TRANSGLUTAMINASE VARIANTS | ROBINSON, HOPE A | 1652 | §112 | Non-Final OA | 20d | AI Ready | Sep 12, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCurie Co. Inc. has 4 pending office actions as of October 2026, spread across 3 art units and 4 examiners.
Irina Neagu has the most, with 1 of Curie Co. Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
